Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026

Rhea-AI Summary

Tenax Therapeutics (Nasdaq: TENX) will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York.

When: February 11, 2026 at 12:30 p.m. ET. Participants: Chris Giordano, President & CEO, and Douglas Randall, Chief Business Officer. A live and archived webcast will be available on the company's investor relations webpage.

News Market Reaction – TENX

+1.39%

1 alert

+1.39% News Effect

On the day this news was published, TENX gained 1.39%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Share price: $12.95 52-week high: $18.38 52-week low: $4.63 +5 more

8 metrics

Share price $12.95 Pre-news current price

52-week high $18.38 52-week range upper bound

52-week low $4.63 52-week range lower bound

Market cap $80,854,296 Equity value prior to news

Volume today 141,170 shares Trading volume on news day

20-day avg volume 341,467 shares Liquidity benchmark

200-day MA $7.75 Long-term trend level

Conference time 12:30 p.m. ET Guggenheim Biotech Summit session on Feb 11, 2026

Market Reality Check

Price: $12.00 Vol: Volume 141,170 is 0.41x t...

low vol

$12.00 Last Close

Volume Volume 141,170 is 0.41x the 20-day average of 341,467, indicating subdued trading ahead of the conference appearance. low

Technical TENX trades above its 200-day moving average of 7.75 with a pre-news price of 12.95, reflecting a sustained uptrend versus longer-term levels.

Peers on Argus

TENX was flat at 0% while several biotech peers traded lower, including ALLR at ...

TENX was flat at 0% while several biotech peers traded lower, including ALLR at -7.67%, ANTX at -3.57%, DARE at -0.56%, and KZR at -1.37%. This suggests the conference participation news was more company-specific than sector-driven.

Historical Context

5 past events · Latest: Dec 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 17	Phase 3 design update	Positive	+5.7%	LEVEL Phase 3 BSSR confirmed >90% power and launch of LEVEL-2 trial.
Nov 25	Investor conferences	Neutral	+4.4%	Announcement of two early-December healthcare conference fireside chats.
Nov 12	Earnings and update	Neutral	-0.7%	Q3 2025 results, LEVEL timelines, patent progress, and cash runway to 2027.
Nov 06	KOL call announcement	Neutral	-2.4%	Planned virtual KOL event to discuss TNX-103 and Phase 3 program.
Nov 03	Guggenheim conference	Neutral	-2.3%	Participation in Guggenheim healthcare conference via fireside chat in Boston.

Pattern Detected

TENX has shown modest, generally aligned price moves around clinical and event-driven updates, with conferences sometimes drawing positive interest.

Recent Company History

Over the last few months, Tenax reported multiple late-stage development milestones for TNX-103 and maintained active investor engagement. A Dec 17 blinded sample size reassessment confirmed >90% power for the Phase 3 LEVEL trial and launch of LEVEL-2, which coincided with a +5.65% move. Earlier, Q3 2025 results on Nov 12 highlighted cash of $99.4M and runway through 2027. Participation in several investor conferences in Nov–Dec 2025 produced modest but generally aligned reactions, providing context for today’s Guggenheim summit appearance.

Market Pulse Summary

This announcement highlights Tenax’s continued investor outreach via a fireside chat at the Guggenhe...

Analysis

This announcement highlights Tenax’s continued investor outreach via a fireside chat at the Guggenheim Emerging Outlook Biotech Summit on Feb 11, 2026. It fits a recent pattern of conference participation alongside key clinical milestones, including the LEVEL Phase 3 update on Dec 17, 2025. Investors may focus on how management frames trial timelines, the broader TNX-103 program, and existing cash runway through 2027, while monitoring upcoming data and additional regulatory or clinical disclosures.

Key Terms

phase 3, cardiopulmonary, webcast

3 terms

phase 3 medical

"a Phase 3, development-stage pharmaceutical company using clinical insights"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

cardiopulmonary medical

"develop novel cardiopulmonary therapies, announced today that the Company"

Relating to the combined function of the heart and lungs—how the heart pumps blood and the lungs oxygenate that blood and remove waste gases. Investors watch cardiopulmonary issues because treatments, devices, or clinical results in this area can affect demand, regulatory reviews, hospital spending and patient outcomes; think of the heart and lungs as a vehicle’s engine and fuel system—if either falters, the market for repairs and improvements can change quickly.

webcast technical

"The live and archived webcast of the presentation will be accessible"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

CHAPEL HILL, N.C., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026, which is taking place from February 11-12, 2026, in New York, NY.

Details of presentation:
Format: Fireside chat
Participants: Chris Giordano, President & Chief Executive Officer; Douglas Randall, Chief Business Officer
Date and Time: February 11, 2026, at 12:30 p.m. ET

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contact:

Investor and Media:

Argot Partners

tenax@argotpartners.com

FAQ

When is Tenax Therapeutics (TENX) presenting at the Guggenheim Emerging Outlook Biotech Summit 2026?

Tenax is presenting on February 11, 2026 at 12:30 p.m. ET. According to the company, the presentation is a fireside chat featuring senior executives and is scheduled during the February 11-12, 2026 summit in New York.

Who will represent Tenax Therapeutics (TENX) in the fireside chat on February 11, 2026?

Chris Giordano and Douglas Randall will represent Tenax in the fireside chat. According to the company, Chris Giordano is President & CEO and Douglas Randall is Chief Business Officer, participating in the February 11 presentation at 12:30 p.m. ET.

How can investors watch the Tenax (TENX) presentation at the Guggenheim biotech summit?

Investors can view a live and archived webcast on Tenax's investor relations webpage. According to the company, the webcast will be accessible both live during the February 11 presentation and archived afterward for later viewing.

What format will Tenax Therapeutics (TENX) use for its Guggenheim summit presentation?

Tenax will present in a fireside chat format with company executives. According to the company, the format is an executive discussion scheduled for February 11, 2026 at 12:30 p.m. ET during the Guggenheim Emerging Outlook Biotech Summit.

Will Tenax (TENX) provide a replay of its Guggenheim Emerging Outlook presentation?

Yes, a replay will be available as an archived webcast on the company's investor relations webpage. According to the company, both the live presentation and an archived version will be accessible after the February 11 session.